Raymond James Financial
PFE icon

Raymond James Financial’s Pfizer PFE Stock Holding History

Raymond James Financial’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-32,100
Closed -$835K – 5301
2025
Q3 		$835K Buy
+32,100
New +$792K ﹤0.01% 3795

Other funds holding PFE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Raymond James Financial's PFE Position: Q2 2026 in Review

Raymond James Financial increased its Pfizer (PFE) stake by 2.3% in Q2 2026, buying an estimated $7.01M and bringing the position to 11,942,054 shares worth $288M. The position accounts for 0.08% of the portfolio, ranked #219.

Raymond James Financial first reported a position in PFE in Q4 2024 and has held it in 7 quarters since. The position peaked at $328M in Q1 2026. 2,840 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Raymond James Financial held 11,942,054 shares of Pfizer worth $288M as of Q2 2026.
  • Raymond James Financial bought 267,838 Pfizer shares in Q2 2026, an estimated $7.01M.
  • Pfizer made up 0.08% of Raymond James Financial's portfolio in Q2 2026, its #219 holding.
  • Raymond James Financial first reported a position in Pfizer in Q4 2024 and has held it in 7 quarters since.
  • Raymond James Financial's Pfizer position peaked at $328M in Q1 2026.
  • 2,840 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.